The peptide craze, in context: what the evidence supports vs. what gets sold

The single most consistent thing about how “peptides” are discussed in 2026 is the imprecision of the word. Three categorically different substances get bundled under the same label by influencers, podcast guests, and occasionally by clinicians who should know better. Pulling them apart is unglamorous work, but it is also the difference between a drug with multibillion-dollar phase-3 cardiovascular trials and a research chemical with seven human subjects to its name.

This piece is the editorial frame for the rest of the site. Each category gets its own coverage on the peptide map; this is why the map is structured the way it is.

What the craze looks like on TikTok

Four feeds, four very different products, all filed by the platform under the same word —

The first two clips are @dr_emilly and @abbeyyung on topical copper peptides — a regulated cosmetic ingredient with moderate but real human data for skin texture and firmness. The third, @jaylanefit, is starting a four-week TB-500 cycle — an injectable research peptide with no FDA approval and trivial human evidence. The fourth, @growthovereverything, asks his followers about BPC-157 with a #joerogan hashtag and links his stack in the bio.

The platform doesn’t distinguish. The hashtag pool is shared, the recommendation algorithm is shared, the affiliate-link grammar (“link in my bio”) is shared. The categories below are.

Category 1: FDA-approved peptide drugs

The visible center of the “craze” is, in terms of drug-development history, mundane: incretin mimetics that work. Semaglutide is FDA-approved as Ozempic, Wegovy, and Rybelsus across diabetes, weight management, cardiovascular event reduction, and (as of August 2025) MASH. Tirzepatide is FDA-approved as Mounjaro and Zepbound across diabetes, chronic weight management, and obstructive sleep apnea. Both compound on a clinical-trial base larger than most 20th-century blockbusters had at peak.

These are real drugs with real labels and real cardiovascular outcome data. They are also peptides. The wellness conversation often lumps them with everything else under “peptide therapy”; the regulatory conversation does not, because the controls and accountability are fundamentally different.

hCG (Pregnyl, Ovitrelle), PT-141 (Vyleesi), Tesamorelin (Egrifta), and Liraglutide (Victoza, Saxenda) are the rest of the FDA-approved peptide canon. None of them are what people mean when they ask about “peptides,” but they should be — these are the indications, side-effect profiles, and price points worth using as the reference point.

Category 2: cosmetic peptides

The cosmetic-peptide conversation is the second layer of confusion. It is fundamentally a different regulatory and clinical world from either FDA-approved drugs or research compounds. GHK-Cu, Argireline, and Matrixyl are listed in the EU CosIng database and the US FDA cosmetics framework as ingredients in topical preparations. The serums on a Sephora shelf containing acetyl hexapeptide-8 are not “the same kind of thing” as injectable ipamorelin, but the marketing language often suggests they are.

These ingredients have a real evidence base for topical anti-aging endpoints — small effect sizes, mostly self-reported, generally below the threshold for FDA cosmetic-vs-drug enforcement. There is no comparable evidence for systemic cosmetic effects. A skincare peptide is, in the regulatory sense, a moisturizer ingredient. Treating it as analogous to an injectable is a category error.

Category 3: research peptides marketed as wellness

The category that defines the “craze” in the cultural sense is the one with the weakest evidence base. BPC-157, MK-677, TB-500, CJC-1295, Ipamorelin, Melanotan II, and the rest of the not-legal-US set are research compounds with substantial preclinical literature, scattered case reports, and very small or absent human-trial data.

The honest editorial position about this category is uncomfortable because it is mostly negative space. There are reasonable preclinical results in rats and mice. There are not reasonable randomized human trials. There are case reports of harm associated with several compounds in this group (Melanotan II in particular). There is a WADA categorization (S0, non-approved substances) that catches the whole category for athletes. There is no jurisdiction in which most of these substances is approved as a drug.

The wellness conversation tends to describe research peptides with the syntactic structure normally reserved for approved drugs (“for joint pain,” “for sleep,” “for tissue repair”). The science does not yet support that syntax. Saying so is not anti-science, and it is not a recommendation to abandon research interest in these compounds. It is the editorial-honest framing of where the evidence currently sits.

The compounding question collapses two of these together

Compounded peptide therapy in the US — the prescriber-and-pharmacy ecosystem reachable through wellness telehealth — operates across Categories 1 and 3 simultaneously. Compounded copies of FDA-approved semaglutide and tirzepatide (Category 1) operate under the “essentially a copy” rule of section 503A; their substance is on neither the 503A nor 503B bulks list, but their parent products are real approved drugs. Compounded BPC-157, ipamorelin, CJC-1295 (Category 3) operate under whatever the prescriber documents as individualized clinical reasoning; the underlying substance has no approved drug parallel.

Patients see one bill, one website, one prescriber. They are buying two regulatory products. The compounding-safety post covers this in more detail.

What the craze actually is

The market, in three sentences:

1. GLP-1 incretin mimetics are a generational pharmacotherapy advance with real cardiovascular and metabolic outcomes. The market response is rational. The compounded supply, the off-label wellness positioning, and the cosmetic-adjacent marketing are second-order effects that should not be confused with the drug science.

2. Cosmetic peptides are an established skincare ingredient category with modest topical effect sizes. They are treated as foundational to “the peptide market” by retail framing and as marginal to it by drug-development framing. Both can be true.

3. Research peptides marketed as wellness are the category where the gap between marketing claims and human evidence is widest. The mechanistic story is plausible and partially supported in animal work. The clinical story is mostly absent. The compounding-policy environment is increasingly skeptical, with FDA Category 2 placements, PCAC reviews, and (for melanotan, BPC-157, and thymosin alpha-1) explicit safety-risk listings.

The work on this site is mostly the work of refusing to collapse those three categories. The peptide map makes the distinction visible: column = mechanism family, row = regulatory tier. The regulatory_status field on every peptide page does the same thing in writing. There is no editorially honest way to say “are peptides good or bad” — the question is malformed. There is a way to say “is this specific peptide, in this specific dose, for this specific indication, supported by this specific evidence” — and to say it with sources. That’s the craze, in context.